 I. To determine the maximum tolerated doses MTD with the combination of MLN8237 and bortezomib. Phase I II. To describe the toxicities associated with the combination of MLN8237 and bortezomib. Phase I III. To evaluate the overall response rate to the combination of MLN8237 and bortezomib in patients with relapsed or refractory multiple myeloma. Phase II 